AIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AIM ImmunoTech Inc is not a strong buy for a beginner, long-term investor at this time due to financial instability, lack of positive trading signals, and uncertain clinical trial outcomes. The stock's technical indicators and financial performance do not support a compelling entry point.
The MACD is slightly positive, indicating weak bullish momentum, but the RSI is neutral and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.562, with no clear breakout or breakdown signals. Short-term price trends suggest a potential decline in the next week and month.
Promising results for Ampligen in clinical trials for late-stage pancreatic cancer (DURIPANC study). Potential for significant updates in June 2026.
Auditor's going concern emphasis indicates financial instability. Extensive testing and uncertain regulatory approvals for Ampligen. Revenue, net income, EPS, and gross margin have significantly declined in the latest quarter.
In Q4 2025, revenue dropped by -53.33% YoY to $21,000, net income fell by -30.03% YoY to -$4,175,000, EPS declined by -84.55% YoY to -1.44, and gross margin dropped by -207.15% YoY to -90.48%. These metrics indicate severe financial challenges.
No recent analyst ratings or price target changes available.
